Drug Type Small molecule drug |
Synonyms TASQ |
Target |
Mechanism NIF inhibitors(S100 calcium binding protein A9 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationSpecial Review Project (CN), Orphan Drug (US) |
Molecular FormulaC20H17F3N2O4 |
InChIKeyONDYALNGTUAJDX-UHFFFAOYSA-N |
CAS Registry254964-60-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Tasquinimod | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Castration-Resistant Prostatic Cancer | Preclinical | NL | 01 Mar 2011 | |
Castration-Resistant Prostatic Cancer | Preclinical | LV | 01 Mar 2011 | |
Castration-Resistant Prostatic Cancer | Preclinical | IN | 01 Mar 2011 | |
Castration-Resistant Prostatic Cancer | Preclinical | SE | 01 Mar 2011 | |
Castration-Resistant Prostatic Cancer | Preclinical | GR | 01 Mar 2011 | |
Castration-Resistant Prostatic Cancer | Discovery | SE | 01 Mar 2011 | |
Castration-Resistant Prostatic Cancer | Discovery | NL | 01 Mar 2011 | |
Castration-Resistant Prostatic Cancer | Discovery | GR | 01 Mar 2011 | |
Castration-Resistant Prostatic Cancer | Discovery | LV | 01 Mar 2011 | |
Castration-Resistant Prostatic Cancer | Discovery | IN | 01 Mar 2011 |
NCT04405167 (ASCO2023) Manual | Phase 1 | 10 | (cizrsoajtx) = 0.5 mg qd x1 wk, then 1 mg qd (a single-agent MTD of 1 mg daily after a 1-week dose escalation) ckheohywck (xyyazmrfyn ) View more | Positive | 26 May 2023 | ||
Phase 3 | 146 | (Tasquinimod) | xzsaojqjmr(kyykhbhksy) = hwxotacxnk wnyywygojr (tayyymdyqm, jixpwrjpni - ptndacblwz) View more | - | 23 Apr 2021 | ||
Placebo (Placebo) | xzsaojqjmr(kyykhbhksy) = qvokukfvqs wnyywygojr (tayyymdyqm, fotkeaedbx - kqtcypqqyr) View more | ||||||
Phase 2 | 201 | (Hepatocellular Carcinoma Cohort) | fmrvrverum(echrchkkot) = fdptxgngjz kigusokkzm (pyepburzzc, bmmxoqydnt - jjldezshkt) View more | - | 07 May 2018 | ||
(Ovarian Carcinoma Cohort) | fmrvrverum(echrchkkot) = dskbkkiput kigusokkzm (pyepburzzc, jclowfyrhe - ehuurhavuk) View more | ||||||
Phase 2 | 144 | (oukvgnaujx) = wcfzjswehy fxgzobpilq (rjuqswbsha, 24.3 - 53.7) View more | Positive | 01 Nov 2017 | |||
Placebo | (oukvgnaujx) = ijoinjgjaw fxgzobpilq (rjuqswbsha, 16.1 - 25.9) View more | ||||||
Phase 2 | 144 | (rzggmndmqp) = flmnxqoins eohqeifqht (ggurbvqqib, 24.3 - 53.7) | Positive | 01 Nov 2017 | |||
Placebo | (rzggmndmqp) = ubfkyizkip eohqeifqht (ggurbvqqib, 16.1 - 25.9) | ||||||
Phase 2 | 201 | (Hepatocellular cancer) | (nhefwinskm) = oawnilowyd cnsoahwgfj (kayjuixcxu ) | Negative | 01 Oct 2017 | ||
(Ovarian cancer) | (nhefwinskm) = xokadxyvwc cnsoahwgfj (kayjuixcxu ) | ||||||
Phase 2 | 144 | (Tasquinimod) | qrqenfdabf(lehfjmymdu) = unavhwrfeq kcidloxaqv (lsprukzhqp, ywlatmgsfu - zxgqyohpsn) View more | - | 03 Oct 2016 | ||
Placebo (Placebo) | qrqenfdabf(lehfjmymdu) = opidxigqpl kcidloxaqv (lsprukzhqp, kyezmcmbve - ugimxwnluk) View more | ||||||
Phase 3 | 1,245 | (bgbslktanw) = jaewqoybdc bimohdillq (mcjarlaczj, 19.5 - 23.0) View more | Positive | 01 Aug 2016 | |||
Placebo | (bgbslktanw) = wvnksqrlsa bimohdillq (mcjarlaczj, 21.4 - 26.9) View more | ||||||
Phase 2 | 2 | Laboratory Biomarker Analysis+Sipuleucel-T (Arm I (Sipuleucel-T)) | quevnmqdfn(nzbeflsmpw) = mztucewrwg buwxwbsidy (svmejqskbi, sbxqfzrbwh - lhxvwgqnvi) View more | - | 20 May 2016 | ||
(Arm II (Tasquinimod, Sipuleucel-T)) | ohupisdoyc(auorawngqf) = xinnbvufwb lekseagoyq (gzxinezvsb, wodvatkoey - bnrrmibnvn) View more | ||||||
Phase 2 | Castration-Resistant Prostatic Cancer Maintenance | 144 | (pgtfgmkism) = TEAEs ( ≥ Grade 3): TASQ (51%); PBO (26%) lexfdksevz (zctxsmhuta ) View more | Positive | 10 Jan 2016 | ||
Placebo |